文献速递慢阻肺呼吸道感染

GOLD 2020科学委员会报告:COVID-19与慢性阻塞性肺疾病

Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

GOLD科学委员会采用既定文献综述方法,概述COVID-19大流行期间慢阻肺患者的管理。报告指出尚不明确慢阻肺患者是否更易感染SARS-CoV-2,并建议在高流行期仅在必要时行肺功能检查,维持原有吸入治疗,并注意鉴别COVID-19与慢阻肺急性加重。

要点

  • 高流行期肺功能检查仅限诊断或术前评估等必需情形
  • 稳定期慢阻肺的吸入激素、长效支气管扩张剂等应按指征继续使用
  • 疑似COVID-19时应考虑SARS-CoV-2检测,并注意与慢阻肺急性加重鉴别

核心结论

  • 尚不明确慢阻肺患者感染SARS-CoV-2的风险是否增加
  • 稳定期慢阻肺治疗药物应按指征继续使用,不应因疫情随意停用
  • 中重度COVID-19需按不断更新的方案治疗,轻症或无症状者按常规慢阻肺方案随访

研究设计与样本

  • GOLD科学委员会采用既定文献综述方法撰写的报告,非原始研究

主要发现

  • 尚不明确慢阻肺患者是否更易感染SARS-CoV-2
  • COVID-19症状与慢阻肺基础症状或急性加重难以鉴别
  • 中重度COVID-19(含住院和肺炎)应采用不断更新的药物治疗方案,包括瑞德西韦、地塞米松和抗凝

关键数值与推荐

  • 高社区流行期肺功能检查仅用于慢阻肺诊断和/或介入操作或手术前评估肺功能状态所必需时
  • 慢阻肺患者应遵守社交距离、洗手、戴口罩等基本感染控制措施
  • 应保持疫苗接种更新,尤其是每年流感疫苗接种
  • 吸入激素、长效支气管扩张剂、罗氟司特或长期大环内酯类应按稳定期慢阻肺管理指征继续使用
  • 慢阻肺急性加重的全身激素和抗生素按常规指征使用

临床怎么用

  • 高流行期推迟非必需肺功能检查,必需时做好防护
  • 稳定期药物不因疫情停用,急性加重按常规指征处理
  • 疑似COVID-19及时检测;中重度者更频繁准确监测,关注氧疗需求
  • 急性呼吸衰竭处理包括氧疗、俯卧位、无创通气及重度ARDS的保护性肺策略

局限性

  • 原文明确指出相关数据有限
  • 尚不明确慢阻肺患者感染SARS-CoV-2风险是否增加

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has raised many questions about the management of patients with chronic obstructive pulmonary disease (COPD) and whether modifications of their therapy are required. It has raised questions about recognizing and differentiating coronavirus disease (COVID-19) from COPD given the similarity of the symptoms. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Science Committee used established methods for literature review to present an overview of the management of patients with COPD during the COVID-19 pandemic. It is unclear whether patients with COPD are at increased risk of becoming infected with SARS-CoV-2. During periods of high community prevalence of COVID-19, spirometry should only be used when it is essential for COPD diagnosis and/or to assess lung function status for interventional procedures or surgery. Patients with COPD should follow basic infection control measures, including social distancing, hand washing, and wearing a mask or face covering. Patients should remain up to date with appropriate vaccinations, particularly annual influenza vaccination. Although data are limited, inhaled corticosteroids, long-acting bronchodilators, roflumilast, or chronic macrolides should continue to be used as indicated for stable COPD management. Systemic steroids and antibiotics should be used in COPD exacerbations according to the usual indications. Differentiating symptoms of COVID-19 infection from chronic underlying symptoms or those of an acute COPD exacerbation may be challenging. If there is suspicion for COVID-19, testing for SARS-CoV-2 should be considered. Patients who developed moderate-to-severe COVID-19, including hospitalization and pneumonia, should be treated with evolving pharmacotherapeutic approaches as appropriate, including remdesivir, dexamethasone, and anticoagulation. Managing acute respiratory failure should include appropriate oxygen supplementation, prone positioning, noninvasive ventilation, and protective lung strategy in patients with COPD and severe acute respiratory distress syndrome. Patients who developed asymptomatic or mild COVID-19 should be followed with the usual COPD protocols. Patients who developed moderate or worse COVID-19 should be monitored more frequently and accurately than the usual patients with COPD, with particular attention to the need for oxygen therapy.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Halpin DMG, Criner GJ, Papi A, et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2021. PMID: 33146552. doi:10.1164/rccm.202009-3533SO

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。